



Consolidated Financial Results
for the Second Quarter of the Fiscal Year Ending March 31, 2018
[Based on Japanese GAAP]

November 8, 2017

Name of Listed Company: Meiji Holdings Co., Ltd. Listed exchange: 1st Section, Tokyo Stock Exchange
 Code Number: 2269 URL: www.meiji.com
 Representative: Masahiko Matsuo, President and Representative Director
 Inquiries: Jun Furuta, Member of the Board and Executive Officer, General Manager of PR&IR Dept.
 Telephone: +81-3-3273-3917

Submission of quarterly report: November 10, 2017
 Dividend payment commencement: December 6, 2017
 Preparation of explanatory materials for quarterly financial results: Yes
 Holding of a briefing on quarterly financial results: Yes

(Amounts are rounded down to the nearest million yen.)

1. Consolidated Financial Results for the First Six Months of the Fiscal Year Ending March 31, 2018
(April 1, 2017 to September 30, 2017)

(1) Consolidated operating results (% of change from the previous fiscal year)

	Net Sales		Operating Income		Ordinary Income		Net income attributable to shareholders of parent company	
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%
First six months ended								
September 30, 2017	611,494	0.8	45,127	20.9	46,116	27.8	31,433	29.2
September 30, 2016	606,789	2.4	37,322	11.7	36,072	1.4	24,321	-26.6

(Note) Comprehensive income: First six months ended September 30, 2017: JPY 36,673 million (206.1%)
 First six months ended September 30, 2016: JPY 11,979 million (-62.1%)

	Net Income per Share	Diluted Net Income per Share
First six months ended	Yen	Yen
September 30, 2017	216.33	—
September 30, 2016	165.20	—

(2) Consolidated financial position

	Total Assets	Net Assets	Equity Ratio	Net Assets per Share
	Millions of yen	Millions of yen	%	Yen
As of September 30, 2017	918,967	469,651	50.2	3,183.71
As of March 31, 2017	883,895	457,190	50.8	3,064.91

(Reference) Shareholders' equity: As of September 30, 2017: JPY 461,658 million
 As of March 31, 2017: JPY 448,901 million

Disclaimer: These financial statements have been prepared in accordance with generally accepted accounting principles in Japan.
 This English translation is prepared for the reader's convenience. When there are any discrepancies between the original Japanese version and English translation version, the original Japanese version always prevails.

2. Dividends

	Cash Dividends Per Share				
	1Q	2Q	3Q	Financial year end	Annual
Fiscal year ended (or ending)	Yen	Yen	Yen	Yen	Yen
March 31, 2017	—	45.00	—	65.00	110.00
March 31, 2018	—	57.50			
March 31, 2018 (Projected)			—	57.50	115.00

(Note) Amendment to projected dividends recently announced: None

* Breakdown of FYE March 2017 year-end dividend: Ordinary dividend JPY 45.00 and commemorative dividend JPY 20.00.

3. Forecasts of Consolidated Financial Results for the Fiscal Year Ending March 31, 2018

(April 1, 2017 to March 31, 2018)

(% of change from the previous fiscal year)

	Net Sales		Operating Income		Ordinary Income		Net Income attributable to shareholders of parent company		Net Income per Share
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%	Yen
Full year	1,262,300	1.6	96,500	9.2	97,500	9.7	64,500	6.1	443.88

(Note) Amendment to forecasts of consolidated financial results recently announced: Yes

For details, refer to page 5 of “1. Qualitative Information, (3) Explanation Concerning Forecasts for Consolidated Earnings.”

*Notes

(1) Changes in significant subsidiaries during the current fiscal year under review

(Changes in subsidiaries affecting the scope of consolidation): None

(2) Application of specific accounting treatments in the preparation of quarterly consolidated financial statements: Yes

(Note) For details, refer to page 12 of “2. Quarterly Consolidated Financial Statements (4) Notes Concerning Quarterly Financial Statements (Adoption of Special Accounting Methods for Preparation of Quarterly Consolidated Financial)”

(3) Changes in accounting policy, changes in accounting estimates, restatements

1. Changes in accounting policy due to revisions of accounting standards: None

2. Other changes in accounting policy: None

3. Changes in accounting estimates: None

4. Restatements: None

(4) Number of shares outstanding (common stock)

1. Number of shares outstanding at end of period (including treasury stock)	As of Sep. 30, 2017	152,683,400 shares	As of Mar. 31, 2017	152,683,400 shares
2. Number of treasury stock at end of period	As of Sep. 30, 2017	7,676,981 shares	As of Mar. 31, 2017	6,218,500 shares
3. Average number of shares during period	As of Sep. 30, 2017	145,308,427 shares	As of Sep. 30, 2016	147,219,782 shares

* The financial results report is not subject to audit.

* Forward-looking statements and other special notes

(Notice concerning forward-looking statements)

The forward-looking statements described in this document, such as business forecasts, are based on information available at the time of the release of these materials and reasonable assumptions made by the Company, and do not represent a commitment from the Company that they will be achieved. For earnings forecasts assumptions and other related items, refer to page 5 of “1. Qualitative Information, (3) Explanation Concerning Forecasts for Consolidated Earnings

(Explanatory material for financial results)

Explanatory materials for financial results are disclosed through TDnet together with these financial statements. This information is also posted on our website on the same day.

1. Qualitative Information

(1) Explanation Concerning Operating Results

(Millions of yen)

First Six Months Ended	Net Sales	Operating Income	Ordinary Income	Net income attributable to shareholders of parent company	Net Income per Share (Yen)
September 30, 2017	611,494	45,127	46,116	31,433	216.33
September 30, 2016	606,789	37,322	36,072	24,321	165.20
% of YoY Change	0.8	20.9	27.8	29.2	—

The Japanese economy during the first six months of FYE March 2018 transitioned on a mild recovery trend. We saw continued improvement in the corporate earnings and the hiring environment as well as improved consumer spending and capital expenditures. Although economic growth is expected to continue, we should pay attention to overseas economic trends and their impact on the Japanese economy.

Amid such conditions, the Meiji Group entered the final year of STEP UP 17, the Group's Medium-Term Business Plan. Based on our core policy of *Accelerating growth and achieving further improvement in profitability*, we promote our growth strategy aimed at increasing corporate value. These initiatives include *Strengthening priority businesses and taking on the challenge of future growth*, *Improving profitability to withstand harsh economic environments*, *Pursuing global expansion*, and *Evolving our management system*.

In the food segment, we will grow our core products while working to optimize production, distribution, and sales as well as cost reductions towards steady growth.

In the pharmaceutical business, ongoing discussion about fundamental reforms to the NHI pricing system makes us difficult to forecast the future of pharmaceutical industry. We are concentrating business resources on the core domains of anti-infective drugs and CNS agents to maximize sales and profits.

These factors resulted in net sales of JPY 611,494 million (up 0.8%, year on year), operating income of JPY 45,127 million (up 20.9%, year on year), ordinary income of JPY 46,116 million (up 27.8%, year on year) during the first six month of FYE March 2018. Net income attributable to shareholders of parent company was JPY 31,433 million (up 29.2%, year on year).

Below is an overview by segment.

(Millions of yen)

	Reporting Segments			Adjustments	Amount Presented in Consolidated Statements of Income
	Food	Pharmaceuticals	Total		
Net Sales	534,274	77,780	612,055	-560	611,494
Operating Income	40,907	4,354	45,261	-133	45,127

(i) Food segment

(Millions of yen)

	First six months of FYE March 2017 (from Apr. 1, 2016 to Sep. 30, 2016)	First six months of FYE March 2018 (from Apr. 1, 2017 to Sep. 30, 2017)	% of YoY Change
Net Sales	535,298	534,274	-0.2
Operating Income	38,819	40,907	5.4

Overall net sales were largely unchanged year on year. Net sales of international business increased significantly, and net sales of nutrition business increased year on year. Net sales of fresh and fermented dairy business and confectionery business were largely unchanged year on year. Net sales of processed food business declined year on year due to decrease in sales of ice cream.

Operating income increased year on year. Operating income of confectionery business increased significantly year on year due to an improved product mix thanks to the growth of mainstay products. Operating income of international business increased significantly, and operating income of fresh and fermented dairy business and nutrition business increased year on year. Operating income of processed food business declined year on year due to decrease in sales and increase in raw material procurement costs.

Below is an overview of businesses in this segment.

- Fresh and Fermented Dairy business (Yogurt, drinking milk, beverages, etc.)
 - Net sales of functional yogurt increased year on year. Net sales of *Meiji Probio Yogurt R-1* increased significantly thanks to aggressive advertising campaigns and efforts to create attractive visual store displays. Net sales of *Meiji Probio Yogurt LG21* decreased significantly year on year due to falling back in sales following a sales increase after package renewal in March 2016.
 - Net sales of *Meiji Bulgaria Yogurt* declined year on year due to a temporary market shrink following major market expansion during the previous fiscal year.
 - Net sales of drinking milk increased year on year. Our mainstay product *Meiji Oishii Gyunyu* grew thanks to expanded demand. Sales of *Meiji Oishii Gyunyu* (900ml), expanding its sales area, were firm.
- Processed Food business (Cheese, butter and margarine, cream, ice cream, frozen food, etc.)
 - Net sales of cheese increased year on year due to the favorable sales of *Meiji Hokkaido Tokachi Camembert Cheese* and *Meiji Hokkaido Tokachi Smart Cheese*.
 - Net sales of margarine increased year on year thanks to the favorable growth of mainstay product *Meiji Cornsoft*.
 - Net sales of ice cream declined significantly year on year due to the unseasonable weather during summer and the impact of change in our transaction system implemented in April 2017.
- Confectionery business (Chocolate, gummy, chewing gum, etc.)
 - Net sales of chocolate increased year on year. Net sales of the *Chocolate Kouka* series and other health-conscious chocolates significantly increased year on year. This was the result of increased interest in the health benefits of the high cocoa content chocolates (dark chocolate). Net sales of premium chocolate *meiji THE Chocolate* increased significantly year on year.
 - Net sales of gummy products increased year on year. Our mainstay brand *Kaju Gummy* and *Poifull* increased year on year.
 - Net sales of chewing gum decreased significantly year on year due to the market decline.
- Nutrition business (Sports nutrition, infant formula, enteral formula, beauty supplement, OTC drugs, etc.)
 - Net sales of sports nutrition increased significantly year on year. Net sales of *SAVAS* increased significantly year on year thanks to increased consumption among competitive athletes and new consumers taking up light to moderate exercise. *VAAM* also increased year on year thanks to contributions from new products and increased new consumer.
 - Net sales of infant formula decreased year on year due to market contraction as a result of declining birth rates.
 - Net sales of enteral formula increased year on year. The market shifting from tube to oral feeding in hospitals and new products contributed to the growth. Net sales of *Meiji Mei Balance Mini-cup* for the consumer market increased thanks to contributions from new products and enhanced promotional activities.
 - In the beauty supplement, net sales of *Amino Collagen* decreased significantly year on year.

■ Other business (International, food stuffs, livestock products, sugar and corn sweeteners, transportation, etc.)

International

- Among exports, net sales of infant formula to Taiwan and Vietnam grew. Net sales of *Amino Collagen* to Taiwan and Hong Kong were firm.
- Net sales of all businesses in China increased significantly year on year. In the confectionery business, sales of chocolate in Shanghai and Guangzhou were firm. The drinking milk and yogurt business expanded the sales area of drinking milk for the consumer market and lactobacillus beverage. The ice cream business created attractive visual store displays, and launched new products.
- Net sales in the U.S.A. increased significantly year on year thanks to the favorable growth of *Stauffer* products and Meiji brand products, *Hello Panda* and *Chocorooms*.

Others

- Net sales at domestic subsidiaries increased year on year due to expansion of the distribution business and feed business.

(ii) Pharmaceutical segment

(Millions of yen)

	First six months of FYE March 2017 (from Apr. 1, 2016 to Sep. 30, 2016)	First six months of FYE March 2018 (from Apr. 1, 2017 to Sep. 30, 2017)	% of YoY Change
Net Sales	72,128	77,780	7.8
Operating Income	-1,313	4,354	—

Net sales increased year on year. In the domestic ethical pharmaceutical business, sales of both brand name drugs and generics increased year on year. Net sales in the agricultural chemicals and veterinary drugs business decreased year on year.

Operating income increased significantly year on year thanks to increased sales of ethical pharmaceuticals in Japan. Drug marketing costs incurred during the same period of the previous year. Milestone revenues also contributed.

Below is an overview of businesses in this segment.

■ Ethical Pharmaceuticals

Japan

- Net sales of the antibacterial drug *MEIACT* decline significantly year on year due to the replacement by the generic Cefditoren Pivoxil, and promotion of proper use of antibiotics in the systemic antibacterial drug market.
- Net sales of the antidepressant drug *REFLEX* increased year on year thanks to enhanced promotional activities using new evidence obtained for patients in Japan. Net sales of the schizophrenia drug *SYCREST* increased significantly year on year thanks to approval for long term prescription in June 2017.
- Net sales of generic drugs increased significantly year on year. The antibacterial drug *TAZOPIPE Combination for I.V. Infusion Meiji* increased significantly year on year due to approval for additional indication and the acceleration of the market's shift to generics.
- We recorded milestone revenue from Eisai Co., Ltd. and F. Hoffmann-La Roche, Ltd.

International

- Net sales of *MEIACT*, our mainstay product in the export business, decreased significantly year on year due to significant decrease in sales.
- Net sales of MEDREICH in India and Meiji Pharma (Shandong) Co., Ltd. in China increased significantly year on year.

■ Agricultural chemicals and veterinary drugs

- Net sales of agricultural chemicals business decreased year on year. Net sales of herbicide *ZAXA* increased significantly year on year. Net sales of rice blast preventative *ORYZEMATE* decreased significantly year on year.
- Net sales of veterinary drugs business decreased year on year. Net sales of livestock drugs were largely unchanged year on year. Net sales of companion animal drugs decreased significantly year on year.

(2) Explanation Concerning Financial Status

(i) Assets, Liabilities, and Net Assets

[Assets]

For the six months of FYE March 2018, total assets increased year by year by JPY 35,072 million to JPY 918,967 million. Although cash and deposits and other current assets decreased by JPY 6,087 million and JPY 3,645 million, respectively, construction in progress, notes and accounts receivable, investment securities, raw materials and supplies, goods and products, and buildings and structures increased by JPY 12,537 million, JPY 10,877 million, JPY 8,135 million, JPY 5,456 million, JPY 3,298 million, and JPY 3,123 million, respectively.

[Liabilities]

For the six months of FYE March 2018, total liabilities increased year by year by JPY 22,611 million to JPY 449,316 million. Although long term debt decreased by JPY 8,464 million, short-term loans payable, notes and accounts payable, commercial paper, and other current liabilities increased by JPY 10,614 million, JPY 8,284 million, JPY 8,000 million, and JPY 4,095 million, respectively.

[Net Assets]

For the six months of FYE March 2018, total net assets increased year by year by JPY 12,460 million to JPY 469,651 million. Although treasury stock increased by JPY 13,880 million (net assets decreased), retained earnings and net unrealized holding gain or losses on securities increased by JPY 21,913 million and JPY 4,729 million, respectively.

Our equity ratio decreased from 50.8% as of the previous consolidated accounting period to 50.2%.

(ii) Cash Flows

(Millions of yen)

	First six months of FYE March 2016 (from Apr. 1, 2016 to Sep.30, 2016)	First six months of FYE March 2017 (from Apr. 1, 2017 to Sep.30, 2017)	Change
Net cash flow from operating activities	23,667	38,700	15,033
Net cash flow from investing activities	-19,740	-32,675	-12,935
Net cash flow from financing activities	-13,980	-11,026	2,953
Translation adjustment on cash and cash equivalents	-1,559	-284	1,275
Net increase (decrease) in cash and cash equivalents	-11,613	-5,286	6,327
Cash and cash equivalents at beginning of year	31,516	22,624	-8,891
Increase in cash and cash equivalents from newly consolidated subsidiary	378	—	-378
Cash and cash equivalents at end of period	20,281	17,338	-2,942

Cash flow from business activities increased by 15,033 million yen year-on-year to 38,700 million yen. This was due to a decrease in the payment amount for corporate taxes.

Cash flow from investment activities decreased by 12,935 million yen year-on-year to 32,675 million yen. This was due to an increase in payments for purchases of property, plants, or equipment.

Accordingly, free cash flow (total of cash flow from business activities and cash flow from investment activities) increased by 2,098 million yen year-on-year to income totaling 6,025 million yen.

Cash flows from financing activities resulted in expenditures of 11,026 million yen, a 2,953 million yen decrease in expenditures compared to the previous consolidated fiscal period.

As a result, cash and cash equivalents as of the end of the consolidated fiscal period under review were 17,338 million yen.

(3) Explanation Concerning Forecasts for Consolidated Earnings

Compared to the full-year consolidated earnings forecasts published in our Consolidated Earnings Report of the FYE March 2018 released on May 12, 2017, we conducted an upward revision for net sales, operating income, ordinary income, and net income attributable to shareholders of parent company.

The revision was conducted because cost reduction initiatives in the food segment conducted during the cumulative second quarter progressed ahead of schedule.

■ Revisions to Financial Forecasts for the Fiscal Year Ending March 31, 2018 (April 1, 2017 to March 31, 2018)

	Net sales	Operating income	Ordinary income	Net income attributable to shareholders of parent company	Net income per share
	millions of yen	millions of yen	millions of yen	millions of yen	yen
Previous forecasts (A)	1,261,000	94,500	95,000	61,000	414.56
Revised forecasts (B)	1,262,300	96,500	97,500	64,500	443.88
Change (B-A)	1,300	2,000	2,500	3,500	
Percentage of change	0.1	2.1	2.6	5.7	
(Reference) Actual results for the fiscal year ended March 31, 2017	1,242,480	88,395	88,839	60,786	413.11

2. Quarterly Consolidated Financial Statements

(1) Quarterly Consolidated Balance Sheets

(Millions of yen)

	As of March 31, 2017	As of September 30, 2017
ASSETS		
Current assets		
Cash and deposits	24,761	18,674
Notes and accounts receivable	183,807	194,684
Goods and products	88,524	91,823
Work in process	4,114	4,074
Raw materials and supplies	41,596	47,052
Others	35,274	31,629
Allowance for doubtful accounts	-370	-201
Total current assets	377,707	387,737
Fixed assets		
Property, plants and equipment		
Buildings and structures	301,158	306,803
Less accumulated depreciation	-172,253	-174,775
Buildings and structures (net)	128,904	132,028
Machinery and equipment	501,254	504,709
Less accumulated depreciation	-372,520	-375,052
Machinery and equipment (net)	128,734	129,657
Tools and furniture	52,383	53,277
Less accumulated depreciation	-42,204	-42,818
Tools and furniture (net)	10,178	10,458
Land	72,603	73,835
Lease assets	3,972	3,051
Less accumulated depreciation	-3,140	-2,295
Lease assets (net)	832	755
Construction in progress	24,733	37,270
Total property, plants and equipment	365,986	384,005
Intangible assets		
Goodwill	12,840	12,069
Other	13,096	12,371
Total intangible assets	25,936	24,441
Investments and other fixed assets		
Investment securities	77,862	85,997
Net defined benefit asset	20,418	21,258
Other	16,092	15,634
Allowance for doubtful accounts	-107	-109
Total investments and other fixed assets	114,264	122,782
Total fixed assets	506,187	531,229
Total assets	883,895	918,967

(Millions of yen)

	As of March 31, 2017	As of September 30, 2017
LIABILITIES		
Current liabilities		
Notes and accounts payable	110,730	119,014
Short-term bank loans	50,574	61,189
Current portion of bonds	30,000	20,000
Commercial paper	-	8,000
Income taxes payable	17,457	15,445
Accrued bonuses for employees	10,512	9,957
Allowance for sales returns	132	70
Allowance for sales rebates	2,061	2,048
Other current liabilities	92,722	96,818
Total current liabilities	314,191	332,545
Long-term liabilities		
Bonds	-	10,000
Long-term debt	48,923	40,458
Retirement benefit liabilities	48,371	49,010
Reserve for directors' retirement benefits	150	138
Other long-term liabilities	15,067	17,163
Total long-term liabilities	112,513	116,771
Total liabilities	426,704	449,316
NET ASSETS		
Shareholders' equity		
Common stock	30,000	30,000
Capital surplus	99,762	99,766
Retained earnings	322,856	344,770
Treasury stock, at cost	-16,607	-30,488
Total shareholders' equity	436,011	444,047
Accumulated other comprehensive income		
Net unrealized holding gains or losses on securities	25,120	29,850
Deferred gains or losses on hedges	-5	56
Foreign currency translation adjustments	1,181	-119
Adjusted cumulative of retirement benefits	-13,406	-12,176
Total accumulated other comprehensive income	12,890	17,611
Minority interests	8,289	7,992
Total net assets	457,190	469,651
Total liabilities and net assets	883,895	918,967

(2) Quarterly Consolidated Statements of Income and Consolidated Statements of Comprehensive Income
(Quarterly Consolidated Statements of Income)
(For the First Six Months Ended September 30, 2017)

(Millions of yen)

	First six months of FYE March 2017 (from Apr. 1, 2016 to Sep. 30, 2016)	First six months of FYE March 2018 (from Apr. 1, 2017 to Sep. 30, 2017)
Net sales	606,789	611,494
Cost of sales	386,799	391,893
Gross profit	219,989	219,601
Selling, general and administrative expenses	182,666	174,473
Operating income	37,322	45,127
Non-operating income		
Interest income	61	69
Dividend income	622	664
Equity in income of affiliates	-	317
Foreign exchange gains	-	147
Other	704	742
Total non-operating income	1,389	1,942
Non-operating expenses		
Interest expenses	423	382
Share of loss of entities accounted for using equity method	168	-
Foreign exchange losses	1,617	-
Other	430	571
Total non-operating expenses	2,639	953
Ordinary income	36,072	46,116
Extraordinary income		
Gain on sale of property, plants and equipment	5,142	2,672
Gain on liquidation of subsidiaries	-	464
Other	228	252
Total extraordinary income	5,370	3,390
Extraordinary losses		
Loss on disposal of property, plants and equipment	1,039	2,039
Loss on sales of shares of subsidiaries and associates	-	444
Impairment loss	51	114
Loss on disaster	1,295	-
Other	177	61
Total extraordinary losses	2,563	2,659
Income before income taxes	38,878	46,847
Income taxes	14,515	14,856
Net income	24,363	31,990
Net income or net losses attributable to non-controlling shareholders	42	557
Net income attributable to shareholders of parent company	24,321	31,433

(Quarterly Consolidated Statements of Comprehensive Income)
(For the First Six Months Ended September 30, 2017)

(Millions of yen)

	First six months of FYE March 2017 <small>(from Apr. 1, 2016 to Sep. 30, 2016)</small>	First six months of FYE March 2018 <small>(from Apr. 1, 2017 to Sep. 30, 2017)</small>
Net income	24,363	31,990
Other comprehensive income		
Net unrealized holding gains or losses on securities	-3,966	4,733
Deferred gains or losses on hedges	-153	62
Foreign currency translation adjustments	-8,658	-1,477
Adjustments related to retirement benefits	1,472	1,230
Equity in affiliates accounted for by equity method	-1,078	133
Total other comprehensive income	-12,383	4,682
Comprehensive income	11,979	36,673
(Breakdown)		
Comprehensive income attributable to shareholders of parent company	12,238	36,154
Comprehensive income attributable to minority shareholders	-258	518

(3) Quarterly Consolidated Statements of Cash Flow

(Millions of yen)

	First six months of FYE March 2017 (from Apr. 1, 2016 to Sep. 30, 2016)	First six months of FYE March 2018 (from Apr. 1, 2017 to Sep. 30, 2017)
Cash flows from operating activities		
Income before income taxes	38,878	46,847
Depreciation and amortization	22,198	22,401
Impairment loss	51	114
Amortization of goodwill	784	823
Loss on disposal of property, plants and equipment	1,034	2,039
Increase (decrease) in allowance for doubtful accounts	360	-159
Increase (decrease) in accrued bonuses to employees	-277	-553
Increase (decrease) in retirement benefit liabilities	1,447	1,578
Interest and dividends received	-684	-734
Interest expenses	423	382
Equity in loss (income) of equity-method affiliates	168	-317
Loss (gain) on sale of property, plants or equipment	-5,128	-2,647
Loss (gain) on sale of investment securities	16	-246
Decrease (increase) in trade receivables	7,578	-11,258
Decrease (increase) in inventories	-9,630	-9,341
Increase (decrease) in trade payables	533	9,518
Others	-7,892	-4,968
Subtotal	49,862	53,478
Interest and dividends received	684	741
Interest expenses paid	-386	-414
Income taxes paid	-26,493	-15,103
Net cash provided by operating activities	23,667	38,700
Cash flows from financing activities		
Payments for purchases of property, plants or equipment	-22,610	-33,929
Payments for purchases of intangible fixed assets	-702	-906
Proceeds from sales of property, plants or equipment and intangible fixed assets	5,675	3,807
Proceeds from sales of investments in real estate	118	1
Payments for purchases of investment securities	-501	-1,007
Proceeds from sales of investment securities	51	364
Others	-1,772	-1,006
Net cash used in investing activities	-19,740	-32,675

(Millions of yen)

	First six months of FYE March 2017 (from Apr. 1, 2016 to Sep. 30, 2016)	First six months of FYE March 2018 (from Apr. 1, 2017 to Sep. 30, 2017)
Cash flows from financing activities		
Increase (decrease) in short-term bank loans	10,349	10,410
Increase (decrease) in commercial paper	8,000	8,000
Proceeds from long-term loans payable	1,207	3,157
Repayment of long-term loans payable	-2,221	-11,581
Proceeds from issuance of bonds	-	9,955
Redemption of bonds	-20,000	-10,000
Decrease (increase) in treasury stock	-24	-10,053
Cash dividends paid	-9,165	-9,499
Cash dividends paid to minority shareholders	-127	-92
Payments from changes in ownership interests in subsidiaries that do not result in change in scope of consolidation	-955	-817
Others	-1,042	-506
Net cash used in financing activities	-13,980	-11,026
Translation adjustment on cash and cash equivalents	-1,559	-284
Net increase (decrease) in cash and cash equivalents	-11,613	-5,286
Cash and cash equivalents at beginning of year	31,516	22,624
Increase in cash and cash equivalents from newly consolidated subsidiary	378	-
Cash and cash equivalents at end of period	20,281	17,338

(4) Notes Concerning Quarterly Financial Statements

(Notes Concerning the Premise of a Going Concern)

Not applicable.

(Notes Concerning Significant Changes in Shareholders' Equity (if any))

Not applicable.

(Adoption of Special Accounting Methods for Preparation of Quarterly Consolidated Financial Statements)

Tax expenses are calculated by rationally estimating the effective tax rate after application of tax effect accounting to income before income taxes for the consolidated fiscal year, which includes the current quarter under review, then multiplying income before income taxes by the estimated effective tax rate.

Income taxes-deferred are shown included in income taxes.

I. The First Six Months of the Previous Consolidated Fiscal Year (April 1, 2016 to September 30, 2016)

1. Information on amounts of sales and income/losses for each reporting segment

(Millions of yen)

	Reporting Segments		Total	Adjustments (Note 1)	Amount Presented in Statements of Income (Note 2)
	Food	Pharmaceuticals			
Net Sales					
(1) Sales to Outside Customers	535,105	71,683	606,789	-	606,789
(2) Inter-segment Sales and Transfers	192	444	637	-637	-
Total	535,298	72,128	607,426	-637	606,789
Income / loss by Segment	38,819	-1,313	37,506	-183	37,322

(Notes)

1. Details of Adjustments are as follows:

The segment income adjustment of a negative JPY 183 million includes inter-segment eliminations of JPY 38 million and a negative JPY 222 million in corporate expenses that are not allocated to individual reporting segments. Corporate expenses mainly consist of administrative expenses for the Company (the holding company).

2. Segment income is adjusted to the operating income recorded in the quarterly consolidated statements of income.

2. Information on impairment loss on fixed assets or good will, etc., for each reporting segment

(Significant impairment loss on fixed assets)

There was no significant impairment loss on fixed assets.

(Significant changes in the amount of goodwill)

There were no significant changes in the amount of goodwill.

(Significant gain on negative goodwill)

No significant negative goodwill was generated.

II The First Six Months of the Consolidated Fiscal Year under Review (April 1, 2017 to September 30, 2017)

1. Information on amounts of sales and income/losses for each reporting segment

(Millions of yen)

	Reporting Segments		Total	Adjustments (Note 1)	Amount Presented in Statements of Income (Note 2)
	Food	Pharmaceuticals			
Net Sales					
(1) Sales to Outside Customers	534,038	77,456	611,494	-	611,494
(2) Inter-segment Sales and Transfers	236	324	560	-560	-
Total	534,274	77,780	612,055	-560	611,494
Income by Segment	40,907	4,354	45,261	-133	45,127

(Notes)

1. Details of Adjustments are as follows:

The segment income adjustment of a negative JPY 133 million includes inter-segment eliminations of JPY 6 million and a negative JPY 139 million in corporate expenses that are not allocated to individual reporting segments. Corporate expenses mainly consist of administrative expenses for the Company (the holding company).

2. Segment income is adjusted to the operating income recorded in the quarterly consolidated statements of income.

2. Information on impairment loss on fixed assets or good will, etc., for each reporting segment

(Significant impairment loss on fixed assets)

There was no significant impairment loss on fixed assets.

(Significant changes in the amount of goodwill)

There were no significant changes in the amount of goodwill.

(Significant gain on negative goodwill)

No significant negative goodwill was generated.

Consolidated Financial Results for the Second Quarter Fiscal Year Ending March 31, 2018 - Supplementary Explanatory Data -

Contents

1. Consolidated Financial Results	1
2. Segment Information	4
3. Analysis of Operating Income	6
4. Consolidated Financial Positions	7
5. Capital Expenditures, Depreciation, R&D Expenses	8
6. Financial Indicators, consolidated	8
7. Sales by Main Products	9
8. Other	
1. (Ref.) Net Sales of Exports and Foreign Consolidated Group Companies	11
2. Pharmaceuticals Pipeline	11

meiji

Meiji Holdings Co., Ltd.

*This document has been translated from the original Japanese as a guide for non-Japanese investors.

*Unaudited figures are included in these materials for reference.

*The forward-looking statements described in this document, such as business forecasts, are based on information available at the time of the release of this presentation and reasonable assumptions made by the Company, and do not represent a commitment from the Company that they will be achieved. The initial plan figures were announced on May 12, 2017.

*Figures of total infectious diseases for the first quarter (on page 10) are revised on November 8, 2017.

(Amounts appearing in the tables below have been rounded down to nearest 100 million yen)

1. Consolidated Financial Results

1. Consolidated Operating Results

(Billions of yen)

FYE March 2018	Q1		Q1-Q2			Q1-Q3		Full-year			
	YoY change	H1 plan achievement rate	YoY change	vs. H1 plan	YoY change	Full-year plan achievement rate	YoY change	vs. Full-year plan			
	%	%	%	%	%	%	%	%			
Net sales	301.3	+0.1	49.5	611.4	+0.8	+0.4					
Cost of sales	191.6	+0.2	—	391.8	+1.3	—					
Gross profit	109.6	-0.1	—	219.6	-0.2	—					
Selling, general and administrative expenses	85.2	-2.9	—	174.4	-4.5	—					
Carriage and storage charges	12.4	+4.0	—	24.2	-0.4	—					
Sales promotion expenses	30.2	-6.6	—	62.4	-7.2	—					
Labor cost	19.6	+0.4	—	39.2	+0.7	—					
Operating income	24.4	+10.8	59.0	45.1	+20.9	+9.0					
Ordinary income	25.1	+15.2	60.9	46.1	+27.8	+11.7					
Net income attributable to owners of parent	17.0	+1.9	65.4	31.4	+29.2	+20.9					

Plan -- FYE March 2018						
H1 (Q1-Q2) Initial Plan	H1 (Q1-Q2) Results	YoY change	H2 (Q3-Q4) Revised Plan	YoY change	Full-year Revised Plan	YoY change
		%		%		%
609.0	611.4	+0.8	650.8	+2.4	1,262.3	+1.6
—	391.8	+1.3	—	—	—	—
—	219.6	-0.2	—	—	—	—
—	174.4	-4.5	—	—	—	—
—	24.2	-0.4	—	—	—	—
—	62.4	-7.2	—	—	—	—
—	39.2	+0.7	—	—	—	—
41.4	45.1	+20.9	51.3	+0.4	96.5	+9.2
41.3	46.1	+27.8	51.4	-2.6	97.5	+9.7
26.0	31.4	+29.2	33.4	-8.4	64.5	+6.1

FYE March 2017	Q1		Q1-Q2			Q1-Q3		Full-year				
	YoY change	H1 plan achievement rate	YoY change	vs. H1 plan	YoY change	Full-year plan achievement rate	YoY change	vs. Full-year plan				
	%	%	%	%	%	%	%	%				
Net sales	301.0	+2.7	49.7	606.7	+2.4	+0.1	934.0	+2.2	74.7	1,242.4	+1.5	-0.7
Cost of sales	191.2	+1.5	—	386.7	+1.5	—	589.3	+0.8	—	781.1	+0.4	—
Gross profit	109.7	+4.9	—	219.9	+4.1	—	344.6	+4.5	—	461.3	+3.5	—
Selling, general and administrative expenses	87.7	-0.0	—	182.6	+2.6	—	276.7	+2.3	—	372.9	+1.4	—
Carriage and storage charges	11.9	+0.6	—	24.3	+0.9	—	36.7	+3.0	—	48.8	+4.0	—
Sales promotion expenses	32.3	-2.6	—	67.2	-0.5	—	104.3	+0.4	—	141.8	-0.4	—
Labor cost	19.5	-0.3	—	38.9	-0.3	—	58.3	-0.8	—	77.9	-0.6	—
Operating income	22.0	+30.6	67.8	37.3	+11.7	+14.8	67.9	+14.6	80.4	88.3	+13.6	+4.6
Ordinary income	21.8	+25.1	67.2	36.0	+1.4	+11.0	67.3	+7.8	79.8	88.8	+8.6	+5.4
Net income attributable to owners of parent	16.6	-25.0	71.0	24.3	-26.6	+3.5	46.2	-9.6	81.9	60.7	-2.9	+7.6

Results -- FYE March 2017						
H1 (Q1-Q2)	YoY change	H2 (Q3-Q4)	YoY change	Full-year	YoY change	
	%		%		%	
606.7	+2.4	635.6	+0.7	1,242.4	+1.5	
386.7	+1.5	394.3	-0.7	781.1	+0.4	
219.9	+4.1	241.3	+3.1	461.3	+3.5	
182.6	+2.6	190.2	+0.2	372.9	+1.4	
24.3	+0.9	24.5	+7.2	48.8	+4.0	
67.2	-0.5	74.5	-0.3	141.8	-0.4	
38.9	-0.3	39.0	-0.8	77.9	-0.6	
37.3	+11.7	51.0	+15.1	88.3	+13.6	
36.0	+1.4	52.7	+14.1	88.8	+8.6	
24.3	-26.6	36.4	+23.8	60.7	-2.9	

2. Operating Results of Food Segment

(Billions of yen)

FYE March 2018	Q1		Q1-Q2			Q1-Q3			Full-year			
	YoY change	H1 plan achievement rate	YoY change	vs. H1 plan	YoY change	Full-year plan achievement rate	YoY change	vs. Full-year plan	YoY change	vs. Full-year plan		
	%	%	%	%	%	%	%	%	%	%		
Net sales	265.6	-0.8	50.0	534.2	-0.2	+0.6						
Cost of sales	174.1	-0.5	—	353.5	+0.5	—						
Gross profit	91.5	-1.3	—	180.6	-1.6	—						
Selling, general and administrative expenses	69.0	-2.3	—	139.7	-3.5	—						
Carriage and storage charges	11.9	+3.4	—	23.1	-1.2	—						
Sales promotion expenses	27.1	-5.5	—	55.5	-6.5	—						
Labor cost	13.9	+0.6	—	27.7	+0.4	—						
Operating income	22.4	+2.1	57.9	40.9	+5.4	+5.4						
Ordinary income	22.8	+4.8	58.3	41.5	+8.6	+6.0						
Net income attributable to owners of parent	15.6	-6.4	61.1	29.3	+9.3	+14.8						

Plan -- FYE March 2018						
H1 (Q1-Q2) Initial Plan	H1 (Q1-Q2) Results	YoY change	H2 (Q3-Q4) Initial Plan	YoY change	Full-year Revised Plan	YoY change
		%		%		%
531.0	534.2	-0.2	556.0	+1.7	1,090.2	+0.7
—	353.5	+0.5	—	—	—	—
—	180.6	-1.6	—	—	—	—
—	139.7	-3.5	—	—	—	—
—	23.1	-1.2	—	—	—	—
—	55.5	-6.5	—	—	—	—
—	27.7	+0.4	—	—	—	—
38.8	40.9	+5.4	45.2	+2.4	86.1	+3.8
39.2	41.5	+8.6	45.8	+1.3	87.3	+4.6
25.6	29.3	+9.3	30.9	+4.2	60.2	+6.5

FYE March 2017	Q1		Q1-Q2			Q1-Q3			Full-year			
	YoY change	H1 plan achievement rate	YoY change	vs. H1 plan	YoY change	Full-year plan achievement rate	YoY change	vs. Full-year plan	YoY change	vs. Full-year plan		
	%	%	%	%	%	%	%	%	%	%		
Net sales	267.6	+4.7	50.6	535.2	+3.5	+1.1	819.4	+3.0	75.3	1,082.1	+2.0	-0.5
Cost of sales	174.9	+2.3	—	351.6	+1.8	—	532.8	+0.8	—	701.4	+0.1	—
Gross profit	92.6	+9.3	—	183.6	+7.1	—	286.5	+7.1	—	380.7	+5.5	—
Selling, general and administrative expenses	70.6	+0.3	—	144.7	+1.4	—	220.3	+1.7	—	297.7	+1.8	—
Carriage and storage charges	11.5	+0.9	—	23.4	+0.9	—	35.3	+3.0	—	46.9	+4.0	—
Sales promotion expenses	28.6	-2.4	—	59.3	-0.4	—	92.2	+0.6	—	124.6	-0.1	—
Labor cost	13.8	-0.6	—	27.6	-0.2	—	41.4	-0.9	—	55.5	-0.5	—
Operating income	22.0	+53.4	71.0	38.8	+35.1	+25.2	66.2	+30.0	82.8	82.9	+21.5	+3.7
Ordinary income	21.7	+49.6	69.6	38.2	+25.0	+22.3	66.2	+24.9	82.6	83.4	+17.2	+4.1
Net income attributable to owners of parent	16.7	+83.7	72.7	26.8	+41.0	+16.9	44.9	+31.5	84.0	56.5	+21.7	+5.7

Results -- FYE March 2017						
	H1 (Q1-Q2)	YoY change	H2 (Q3-Q4)	YoY change	Full-year	YoY change
		%		%		%
	535.2	+3.5	546.8	+0.5	1,082.1	+2.0
	351.6	+1.8	349.7	-1.5	701.4	+0.1
	183.6	+7.1	197.0	+4.1	380.7	+5.5
	144.7	+1.4	152.9	+2.2	297.7	+1.8
	23.4	+0.9	23.5	+7.3	46.9	+4.0
	59.3	-0.4	65.3	+0.2	124.6	-0.1
	27.6	-0.2	27.8	-0.7	55.5	-0.5
	38.8	+35.1	44.1	+11.6	82.9	+21.5
	38.2	+25.0	45.1	+11.4	83.4	+17.2
	26.8	+41.0	29.6	+8.3	56.5	+21.7

3. Operating Results of Pharmaceuticals Segment

(Billions of yen)

FYE March 2018	Q1		Q1-Q2			Q1-Q3		Full-year			
	YoY change	H1 plan	YoY change	vs. H1 plan	YoY change	Full-year plan	YoY change	vs. Full-year plan	YoY change	vs. Full-year plan	
		achievement rate									achievement rate
Net sales	35.9	%	77.7	%		%		%		%	
Cost of sales	17.7	+6.5	38.7	+7.8							
Gross profit	18.1	45.4	38.9	-1.5							
Selling, general and administrative expenses	16.2	—	34.6	+6.9							
Operating income	1.9	—	4.3	—							
Ordinary income	1.9	+11,900.3	4.4	—							
Net income attributable to owners of parent	1.1	—	1.9	—							

Plan -- FYE March 2018						
H1 (Q1-Q2) Initial Plan	H1 (Q1-Q2) Results	YoY change	H2 (Q3-Q4) Revised Plan	YoY change	Full-year Revised Plan	YoY change
79.0	77.7	%	95.4	%	173.2	%
—	38.7	+7.8	—	+6.6	—	+7.2
—	38.9	+8.8	—	—	—	—
—	34.6	+6.9	—	—	—	—
—	34.6	-8.4	—	—	—	—
2.7	4.3	—	6.6	-7.0	11.0	+90.3
2.2	4.4	—	5.6	-22.0	10.0	+108.6
0.4	1.9	—	2.5	-61.6	4.5	+15.5

FYE March 2017	Q1		Q1-Q2			Q1-Q3		Full-year			
	YoY change	H1 plan	YoY change	vs. H1 plan	YoY change	Full-year plan	YoY change	vs. Full-year plan	YoY change	vs. Full-year plan	
		achievement rate									achievement rate
Net sales	33.7	%	72.1	%	115.6	%	161.6	%		%	
Cost of sales	16.5	-10.5	35.6	-5.3	57.2	-3.7	80.6	-0.4		-1.8	
Gross profit	17.1	43.6	36.4	-1.2	58.4	-6.8	80.9	+1.7		—	
Selling, general and administrative expenses	17.1	—	37.7	-9.0	56.3	+4.7	75.1	-5.0		—	
Operating income	0.0	-14.1	-1.3	—	2.1	-76.3	5.7	+0.1		+15.6	
Ordinary income	-0.3	0.9	-2.3	—	0.8	-91.5	4.7	-55.3		+29.6	
Net income attributable to owners of parent	-0.3	—	-2.6	—	1.2	-78.7	3.8	-24.4		+34.4	

Results -- FYE March 2017						
H1 (Q1-Q2)	YoY change	H2 (Q3-Q4)	YoY change	Full-year	YoY change	
72.1	%	89.4	%	161.6	%	
35.6	-5.3	45.0	+1.2	80.6	-1.8	
36.4	-1.2	44.4	+4.2	80.9	+1.7	
37.7	-9.0	37.3	-1.6	75.1	-5.0	
37.7	+7.6	37.3	-6.6	75.1	+0.1	
-1.3	—	7.0	+37.3	5.7	-42.9	
-2.3	—	7.1	+20.2	4.7	-55.3	
-2.6	—	6.5	+145.9	3.8	-24.4	

2. Segment Information

1. Food Segment

A. Net Sales

(Billions of yen)

FYE March 2018	Q1		Q1-Q2		Q1-Q3		Full-year	
	YoY change	H1 plan achievement rate	YoY change	vs. H1 plan	YoY change	Full-year plan achievement rate	YoY change	vs. Full-year plan
	%	%	%	%	%	%	%	%
Fresh and Fermented Dairy	136.0	-0.6	50.0	272.2	+0.9	-0.0		
Processed Food	44.7	-0.8	50.2	91.9	-2.7	+3.1		
Confectionery	36.2	+0.5	52.0	69.9	+0.0	+0.3		
Nutritionals	24.0	+1.0	49.4	49.0	+1.2	+0.7		
Other	87.8	-0.4	49.1	181.2	+1.6	+1.3		
Elimination	-63.3	—	—	-130.2	—	—		

Plan -- FYE March 2018						
H1 (Q1-Q2) Initial Plan	H1 (Q1-Q2) Results	YoY change	H2 (Q3-Q4) Initial Plan	YoY change	Full-year Revised Plan	YoY change
		%		%		%
272.3	272.2	+0.9	278.4	+1.3	550.7	+1.1
89.2	91.9	-2.7	87.2	-2.6	179.1	-2.7
69.6	69.9	+0.0	92.6	+2.5	162.5	+1.4
48.7	49.0	+1.2	45.8	+5.9	94.8	+3.4
178.9	181.2	+1.6	178.9	-0.9	360.2	+0.3
-127.8	-130.2	—	-127.1	—	-257.3	—

FYE March 2017	Q1		Q1-Q2		Q1-Q3		Full-year					
	YoY change	H1 plan achievement rate	YoY change	vs. H1 plan	YoY change	Full-year plan achievement rate	YoY change	vs. Full-year plan				
	%	%	%	%	%	%	%	%				
Fresh and Fermented Dairy	136.7	+9.4	53.7	269.7	+8.5	+6.0	408.2	+8.7	74.8	544.7	+6.4	-0.1
Processed Food	45.0	-6.4	48.8	94.5	-4.0	+2.3	142.3	-4.4	77.8	184.0	-4.0	+0.6
Confectionery	36.0	+3.0	51.2	69.8	-0.4	-0.7	116.8	+0.3	73.4	160.2	-0.1	+0.7
Nutritionals	23.8	+0.0	47.7	48.4	-1.6	-3.0	72.6	-3.3	78.1	91.7	-4.1	-1.4
Other	88.2	+5.7	49.0	178.4	+4.2	-0.9	271.3	+2.8	76.5	359.0	+2.8	+1.2
Elimination	-62.3	—	—	-125.8	—	—	-192.0	—	—	-257.7	—	—

Results -- FYE March 2017						
H1 (Q1-Q2)	YoY change	H2 (Q3-Q4)	YoY change	Full-year	YoY change	
	%		%		%	%
269.7	+8.5	274.9	+4.5	544.7	+6.4	+6.4
94.5	-4.0	89.5	-3.9	184.0	-4.0	-4.0
69.8	-0.4	90.3	+0.0	160.2	-0.1	-0.1
48.4	-1.6	43.2	-6.8	91.7	-4.1	-4.1
178.4	+4.2	180.6	+1.4	359.0	+2.8	+2.8
-125.8	—	-131.9	—	-257.7	—	—

B. Operating Income

(Billions of yen)

FYE March 2018	Q1		Q1-Q2		Q1-Q3		Full-year	
	YoY change	H1 plan achievement rate	YoY change	vs. H1 plan	YoY change	Full-year plan achievement rate	YoY change	vs. Full-year plan
	%	%	%	%	%	%	%	%
Fresh and Fermented Dairy	13.2	-4.7	55.4	24.6	+2.5	+3.0		
Processed Food	1.8	+5.4	42.0	4.0	-11.5	-8.2		
Confectionery	4.5	+14.7	71.3	7.2	+16.1	+14.4		
Nutritionals	3.8	+6.7	55.9	7.2	+3.1	+6.1		
Other	1.2	+22.7	49.9	3.0	+18.2	+21.9		
Elimination and Corporate expenses	-2.2	—	—	-5.3	—	—		

Plan -- FYE March 2018						
H1 (Q1-Q2) Initial Plan	H1 (Q1-Q2) Results	YoY change	H2 (Q3-Q4) Initial Plan	YoY change	Full-year Revised Plan	YoY change
		%		%		%
23.9	24.6	+2.5	28.2	+1.6	52.8	+2.0
4.3	4.0	-11.5	3.0	+5.9	7.0	-4.8
6.3	7.2	+16.1	12.0	-0.7	19.3	+5.0
6.8	7.2	+3.1	5.5	+21.0	12.7	+10.1
2.5	3.0	+18.2	2.7	-8.9	5.8	+3.6
-5.1	-5.3	—	-6.3	—	-11.6	—

FYE March 2017	Q1		Q1-Q2		Q1-Q3		Full-year					
	YoY change	H1 plan achievement rate	YoY change	vs. H1 plan	YoY change	Full-year plan achievement rate	YoY change	vs. Full-year plan				
	%	%	%	%	%	%	%	%				
Fresh and Fermented Dairy	13.8	+50.5	71.8	24.0	+35.7	+24.3	38.0	+39.1	74.6	51.7	+23.6	+1.7
Processed Food	1.7	+24.5	46.3	4.5	+29.4	+20.4	6.6	+17.4	95.0	7.4	+23.0	+5.4
Confectionery	3.9	+124.6	126.3	6.2	+136.0	+100.1	14.3	+51.9	87.3	18.4	+44.4	+12.2
Nutritionals	3.5	+44.2	55.6	7.0	+26.9	+9.1	10.6	+16.5	90.8	11.5	+19.0	-2.0
Other	1.0	+104.5	103.0	2.5	+117.1	+161.3	4.7	+73.7	93.0	5.5	+72.8	+9.1
Elimination and Corporate expenses	-2.1	—	—	-5.6	—	—	-8.2	—	—	-11.8	—	—

Results -- FYE March 2017						
H1 (Q1-Q2)	YoY change	H2 (Q3-Q4)	YoY change	Full-year	YoY change	
	%		%		%	%
24.0	+35.7	27.7	+14.7	51.7	+23.6	+23.6
4.5	+29.4	2.8	+14.0	7.4	+23.0	+23.0
6.2	+136.0	12.1	+20.2	18.4	+44.4	+44.4
7.0	+26.9	4.5	+8.6	11.5	+19.0	+19.0
2.5	+117.1	3.0	+47.0	5.5	+72.8	+72.8
-5.6	—	-6.1	—	-11.8	—	—

Note: Eliminations within the Food segment include eliminations within each business category and between business categories. Also, general corporate expenses refer to expenses not allocated to any specific business.

2. Pharmaceuticals Segment

(Billions of yen)

FYE March 2018	Q1		Q1-Q2		Q1-Q3		Full-year			
	YoY change	H1 plan achievement rate	YoY change	vs. H1 plan	YoY change	Full-year plan achievement rate	YoY change	vs. Full-year plan		
	%	%	%	%	%	%	%	%		
Ethical Pharmaceuticals	33.2	+8.8	45.6	72.2	+9.8	-0.8				
Agricultural Chemicals and Veterinary Drugs	2.6	-15.7	43.4	5.5	-12.4	-10.4				

Plan -- FYE March 2018						
H1 (Q1-Q2) Initial Plan	H1 (Q1-Q2) Results	YoY change	H2 (Q3-Q4) Revised Plan	YoY change	Full-year Revised Plan	YoY change
		%		%		%
72.8	72.2	+9.8	82.2	+7.7	154.4	+8.6
6.2	5.5	-12.4	13.3	+1.3	18.8	-3.2

FYE March 2017	Q1		Q1-Q2		Q1-Q3		Full-year					
	YoY change	H1 plan achievement rate	YoY change	vs. H1 plan	YoY change	Full-year plan achievement rate	YoY change	vs. Full-year plan				
	%	%	%	%	%	%	%	%				
Ethical Pharmaceuticals	30.5	-10.4	43.6	65.7	-5.0	-6.1	106.0	-3.1	72.9	142.1	-1.1	-2.2
Agricultural Chemicals and Veterinary Drugs	3.1	-11.6	43.7	6.3	-8.0	-13.1	9.6	-9.7	49.3	19.4	-6.2	-0.6


Results -- FYE March 2017						
H1 (Q1-Q2)	YoY change	H2 (Q3-Q4)	YoY change	Full-year	YoY change	
	%		%		%	
65.7	-5.0	76.3	+2.5	142.1	-1.1	
6.3	-8.0	13.1	-5.3	19.4	-6.2	

3. Analysis of Operating Income

1. Results

(Billions of yen)

	Q1				Q1-Q2				Q1-Q3				Full-year			
	Consolidated Total	Food	Pharma	Other	Consolidated Total	Food	Pharma	Other	Consolidated Total	Food	Pharma	Other	Consolidated Total	Food	Pharma	Other
Results -- FYE March 2017	22.0	22.0	0.0	0.0	37.3	38.8	-1.3	-0.2								
Due to increased/decreased sales	+0.1	-0.4	+0.5	—	+1.7	-0.0	+1.7	—								
Costs of goods sold increase	-0.4	-0.4	0.0	—	-1.3	-1.3	0.0	—								
Cost reduction	+2.5	+1.2	+1.3	—	+6.8	+3.0	+3.8	—								
Other (incl. change in results of subsidiaries)	+0.2	+0.0	+0.1	-0.0	+0.6	+0.4	+0.1	+0.1								
Total change	+2.4	+0.4	+1.9	-0.0	+7.8	+2.1	+5.6	+0.1								
Results -- FYE March 2018	24.4	22.4	1.9	0.0	45.1	40.9	4.3	-0.1								



(Breakdown)

*1: [Food] Increase in raw material costs: -1.0, Other: -0.3

*2: [Food] Decrease in promotion expenses: +2.6, Distribution optimization: +0.4
 [Pharma] Decrease in promotion expenses: +3.1, Other cost reduction: +0.7

2. Plan -- FYE March 2018

(Billions of yen)

	H1 (Q1-Q2) Results				H2 (Q3-Q4) Revised Plan				Full-year Revised Plan			
	Consolidated Total	Food	Pharma	Other	Consolidated Total	Food	Pharma	Other	Consolidated Total	Food	Pharma	Other
Results -- FYE March 2017	37.3	38.8	-1.3	-0.2	51.0	44.1	7.0	-0.1	88.3	82.9	5.7	-0.3
Due to increased/decreased sales	+1.7	-0.0	+1.7	—	+1.7	+1.5	+0.2	—	+3.4	+1.5	+1.9	—
Changes in costs of goods sold	-1.3	-1.3	0.0	—	-2.0	-2.0	0.0	—	-3.3	-3.3	0.0	—
Changes in other SG&A expenses	+6.8	+3.0	+3.8	—	+1.6	+1.4	+0.2	—	+8.4	+4.4	+4.0	—
Other (incl. change in results of subsidiaries)	+0.6	+0.4	+0.1	+0.1	-1.0	+0.2	-0.8	-0.4	-0.4	+0.6	-0.7	-0.3
Total change	+7.8	+2.1	+5.6	+0.1	+0.3	+1.1	-0.4	-0.4	+8.1	+3.2	+5.2	-0.3
Plan -- FYE March 2018	45.1	40.9	4.3	-0.1	51.4	45.2	6.6	-0.5	96.5	86.1	11.0	-0.6

4. Consolidated Financial Positions

(Billions of yen)

FYE March 2018	As of Jun. 30		As of Sep. 30		As of Dec. 31		As of Mar. 31	
		Change from the previous fiscal year end		Change from the previous fiscal year end		Change from the previous fiscal year end		Change from the previous fiscal year end
Total assets	891.7	+0.9	918.9	+4.0				
Current assets	373.1	-1.2	387.7	+2.7				
Fixed assets	518.5	+2.4	531.2	+4.9				
Total liabilities	437.1	+2.4	449.3	+5.3				
Current liabilities	321.9	+2.5	332.5	+5.8				
Long-term liabilities	115.1	+2.3	116.7	+3.8				
Total net assets	454.6	-0.6	469.6	+2.7				
Shareholders' equity	431.3	-1.1	444.0	+1.8				
Reference								
Consolidated interest bearing debt	155.5	+20.1	139.6	+7.8				
Food segment assets	624.7	-0.9	659.3	+4.6				
Pharmaceuticals segment assets	212.0	-1.7	210.5	-2.5				

FYE March 2017	As of Jun. 30		As of Sep. 30		As of Dec. 31		As of Mar. 31	
		Change from the previous fiscal year end		Change from the previous fiscal year end		Change from the previous fiscal year end		Change from the previous fiscal year end
Total assets	837.5	-2.2	837.1	-2.2	889.2	+3.9	883.8	+3.2
Current assets	350.2	-3.5	354.6	-2.3	394.6	+8.7	377.7	+4.1
Fixed assets	487.3	-1.2	482.4	-2.2	494.6	+0.3	506.1	+2.6
Total liabilities	418.2	-4.3	416.3	-4.7	446.3	+2.1	426.7	-2.3
Current liabilities	259.0	-6.4	277.7	+0.4	324.7	+17.4	314.1	+13.6
Long-term liabilities	159.2	-0.6	138.5	-13.6	121.5	-24.1	112.5	-29.8
Total net assets	419.3	+0.0	420.8	+0.4	442.9	+5.7	457.1	+9.1
Shareholders' equity	405.2	+2.2	412.8	+4.1	428.1	+7.9	436.0	+9.9
Reference								
Consolidated interest bearing debt	157.2	+6.3	144.4	-2.3	147.2	-0.4	129.4	-12.4
Food segment assets	589.3	-0.5	601.6	+1.6	638.2	+7.8	630.1	+6.4
Pharmaceuticals segment assets	193.9	-3.3	193.7	-3.4	209.8	+4.6	215.8	+7.6

5. Capital Expenditures, Depreciation, R&D Expenses

(Billions of yen)

	FYE March 2015		FYE March 2016		FYE March 2017		FYE March 2018	
	H1	Full-year	H1 (Q1-Q2)	Full-year	H1 (Q1-Q2)	Full-year	H1 (Q1-Q2) Results	Full-year Revised Plan
Capital expenditures	28.4	64.3	24.1	42.3	23.3	50.4	34.8	71.0
Food segment	24.9	55.8	21.2	36.5	20.3	44.3	30.6	59.9
Pharmaceutical segment	3.5	8.5	2.8	5.7	2.9	6.0	4.1	11.1
Corporate or elimination	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Depreciation and amortization	19.9	41.8	19.7	42.0	22.1	45.8	22.3	45.7
Food segment	16.9	35.3	17.3	36.5	19.2	39.9	19.3	39.6
Pharmaceutical segment	2.4	5.4	2.2	5.3	2.8	5.7	2.9	5.9
Corporate or elimination	0.5	1.0	0.1	0.2	0.1	0.2	0.1	0.2
R&D expenses	11.9	26.1	12.9	27.3	12.5	26.1	12.5	26.4
Food segment	6.1	12.5	6.4	12.6	6.1	12.4	5.9	12.6
Pharmaceutical segment	5.7	13.5	6.5	14.6	6.4	13.7	6.5	13.7
Corporate or elimination	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0

6. Financial Indicators, consolidated

	FYE March 2014	FYE March 2015	FYE March 2016	FYE March 2017	
	Full-year	Full-year	Full-year	Full-year	
Net sales	1,148.0 billion yen	1,161.1 billion yen	1,223.7 billion yen	1,242.4 billion yen	
Operating income	36.4 billion yen	51.5 billion yen	77.7 billion yen	88.3 billion yen	
Operating income ratio	3.2 %	4.4 %	6.4 %	7.1 %	
EBITDA	77.6 billion yen	94.0 billion yen	121.6 billion yen	135.8 billion yen	(Note) Op. income + Depreciation and amortization
EBITDA margin	6.8 %	8.1 %	9.9 %	10.9 %	
Net income attributable to shareholders of parent company	19.0 billion yen	30.8 billion yen	62.5 billion yen	60.7 billion yen	
Net income ratio	1.7 %	2.7 %	5.1 %	4.9 %	
Total assets	779.4 billion yen	877.3 billion yen	856.1 billion yen	883.8 billion yen	
Interest bearing debt	198.3 billion yen	221.4 billion yen	147.8 billion yen	129.4 billion yen	
Shareholders' equity	320.4 billion yen	370.3 billion yen	408.8 billion yen	448.9 billion yen	
Shareholders' equity ratio	41.1 %	42.2 %	47.8 %	50.8 %	
Debt/Equity ratio	0.6 %	0.6 %	0.4 %	0.3 %	
ROA	5.0 %	6.5 %	9.4 %	10.2 %	(Note) Ordinary income/Average net assets
ROE	6.0 %	8.9 %	16.1 %	14.2 %	(Note) Net income attributable to shareholders of parent company/Average shareholders' equity
Cash flows from operating activities	63.8 billion yen	86.4 billion yen	105.1 billion yen	81.8 billion yen	
Cash flows from investing activities	-47.2 billion yen	-92.8 billion yen	-9.8 billion yen	-44.2 billion yen	
Free cash flows	16.5 billion yen	△6.3 billion yen	95.3 billion yen	37.5 billion yen	(Note) Cash flows from operating activities + Cash flows from investing activities
Net income per share	129.40 yen	209.79 yen	425.06 yen	413.11 yen	(Note) Net income attributable to shareholders of parent company / (Number of shares outstanding - Number of treasury stock)
Net assets per share	2,175.98 yen	2,515.26 yen	2,777.28 yen	3,064.91 yen	(Note) (Total net assets - Noncontrolling interests) / (Number of shares outstanding - Number of treasury stock)
Cash flow per share	407.55 yen	494.24 yen	710.89 yen	728.21 yen	(Note) (Net income attributable to shareholders of parent company + Depreciation and Amortization) / (Number of shares outstanding - Number of treasury stock)
Cash dividends per share	40.00 yen	50.00 yen	90.00 yen	110.00 yen	
Dividend payout ratio	30.9 %	23.8 %	21.2 %	26.6 %	
Price/Earnings ratio--PER	25.2 times	34.9 times	21.3 times	22.4 times	(Note) Year-end stock price/Net income per share
Price/Book value ratio--PBR	1.5 times	2.9 times	3.3 times	3.0 times	(Note) Year-end stock price/Net assets per share
Price/Cash flow ratio--PCFR	8.0 times	14.8 times	12.7 times	12.7 times	(Note) Year-end stock price/Cash flow per share

Note: The above figures per share are calculated by retroactively applying the number of shares resulting from the stock split conducted on October 1, 2015.

7. Sales by Main Products

1. Food Segment (Non-consolidated)

(Billions of yen)

FYE March 2018	Q1		Q1-Q2			Q1-Q3		Full-year		
	YoY Change	H1 Plan Achievement Rate	YoY Change	vs. H1 Plan	YoY Change	Full-year Plan Achievement Rate	YoY Change	vs. Full-year Plan		
	%	%	%	%	%	%	%	%		
Yogurt	22.1	-5.1	48.2	44.1	-2.5	-4.1				
Meiji Bulgaria Yogurt	20.4	-5.9	48.3	40.9	-2.8	-3.4				
Probiotic yogurts	28.3	+0.2	52.1	54.7	+2.2	+0.6				
Drinking milk	27.5	+1.7	50.2	56.2	+2.4	+2.4				
Meiji Oishii Gyunyu	14.7	+1.4	48.1	30.9	+2.4	+0.6				
Cheese	8.8	-1.5	53.5	17.2	-0.6	+4.3				
Meiji Hokkaido Tokachi series	3.3	+3.9	54.3	6.4	+2.5	+2.6				
Ice cream	11.6	-12.0	43.1	26.5	-12.1	-1.4				
Chocolate	21.7	+5.0	51.4	42.0	+3.6	-0.5				
Nutritional products	12.7	-3.4	48.8	26.2	-0.5	+0.3				
Sports nutrition	5.6	+14.4	51.0	10.9	+11.4	+0.1				

Plan -- FYE March 2018						
H1 (Q1-Q2) Initial Plan	H1 (Q1-Q2) Results	YoY Change	H2 (Q3-Q4) Initial Plan	YoY Change	Full-year Revised Plan	YoY Change
		%		%		%
46.0	44.1	-2.5	43.5	+5.5	87.7	+1.3
42.4	40.9	-2.8	39.2	+2.7	80.2	-0.2
54.4	54.7	+2.2	67.9	+2.9	122.7	+2.6
54.8	56.2	+2.4	50.8	-3.1	107.1	-0.3
30.7	30.9	+2.4	28.0	+1.3	59.0	+1.9
16.5	17.2	-0.6	17.5	-3.6	34.7	-2.1
6.2	6.4	+2.5	6.8	-2.4	13.2	-0.0
26.9	26.5	-12.1	18.1	+0.3	44.6	-7.5
42.3	42.0	+3.6	63.2	+1.9	105.2	+2.5
26.1	26.2	-0.5	26.9	+3.9	53.1	+1.7
10.9	10.9	+11.4	9.2	+24.6	20.2	+17.1

FYE March 2017	Q1		Q1-Q2			Q1-Q3		Full-year				
	YoY Change	H1 Plan Achievement Rate	YoY Change	vs. H1 Plan	YoY Change	Full-year Plan Achievement Rate	YoY Change	vs. Full-year Plan				
	%	%	%	%	%	%	%	%				
Yogurt	23.3	+8.9	54.5	45.2	+5.7	+5.6	66.3	+5.9	75.7	86.5	+4.1	-1.2
Meiji Bulgaria Yogurt	21.7	+11.7	54.3	42.1	+8.0	+5.2	61.6	+7.6	75.6	80.3	+5.5	-1.4
Probiotic yogurts	28.3	+20.4	58.7	53.5	+17.5	+11.1	85.6	+20.5	70.9	119.6	+12.1	-1.0
Drinking milk	27.0	-1.9	49.7	54.8	-2.2	+0.7	81.6	-2.0	76.7	107.4	-1.4	+0.9
Meiji Oishii Gyunyu	14.5	+1.4	49.4	30.1	+0.6	+2.3	44.3	+0.7	76.8	57.9	+0.9	+0.4
Cheese	8.9	+8.7	53.7	17.3	+5.9	+3.7	26.9	+2.7	76.6	35.5	+2.0	+0.8
Meiji Hokkaido Tokachi series	3.2	+8.4	54.5	6.2	+6.2	+4.3	9.9	+3.0	76.7	13.2	+4.4	+1.9
Ice cream ^(Note1)	13.2	-0.3	45.0	30.2	+4.5	+3.1	40.0	+4.7	83.2	48.3	+3.8	+0.2
Chocolate	20.7	+9.7	52.8	40.6	+6.8	+3.7	72.8	+7.9	72.1	102.6	+7.4	+1.7
Nutritional products ^(Note2)	13.2	+9.4	51.6	26.3	+6.9	+3.0	40.8	+5.7	77.5	52.3	+3.9	-0.8
Sports nutrition	4.8	+12.6	48.6	9.8	+12.8	-2.1	13.8	+8.6	78.6	17.3	+6.6	-1.8

Results -- FYE March 2017						
H1 (Q1-Q2)	YoY Change	H2 (Q3-Q4)	YoY Change	Full-year	YoY Change	
	%		%		%	
45.2	+5.7	41.2	+2.3	86.5	+4.1	
42.1	+8.0	38.2	+2.9	80.3	+5.5	
53.5	+17.5	66.0	+8.1	119.6	+12.1	
54.8	-2.2	52.5	-0.6	107.4	-1.4	
30.1	+0.6	27.7	+1.1	57.9	+0.9	
17.3	+5.9	18.1	-1.5	35.5	+2.0	
6.2	+6.2	6.9	+2.8	13.2	+4.4	
30.2	+4.5	18.0	+2.8	48.3	+3.8	
40.6	+6.8	62.0	+7.8	102.6	+7.4	
26.3	+6.9	25.9	+1.0	52.3	+3.9	
9.8	+12.8	7.4	-0.7	17.3	+6.6	

Note: Nutritional products includes infant formula and enteral formula.

2. Pharmaceuticals Segment (Non-consolidated)

(Billions of yen)

FYE March 2018		Q1		Q1-Q2			Q1-Q3		Full-year		
		YoY Change	H1 Plan	YoY Change	vs. H1 Plan	YoY Change	Full-year Plan	YoY Change	vs. Full-year Plan		
			Achievement Rate							Achievement Rate	
		%	%	%	%	%	%	%	%		
Ethical pharma ceuticals	Total brand name drugs	11.8	+4.2	41.1	25.8	+4.7	-10.2				
	MEIACT	1.5	-21.8	41.2	3.4	-20.9	-10.4				
	REFLEX	4.2	-8.2	40.3	9.7	+1.4	-6.7				
	SYCREST	0.5	+60.4	39.6	1.3	+140.2	-10.5				
	BILANOVA	0.2	—	17.5	0.4	—	-63.2				
	Total generic drugs	10.7	+10.7	45.9	23.0	+13.2	-1.6				
	AMLODIPINE	1.0	-1.3	44.0	2.2	+1.4	-5.1				
TAZOPIPE	0.9	+177.3	52.7	2.1	+153.8	+17.4					
(By field)	Total infectious diseases*	8.1	+1.4	45.4	17.6	+3.3	-1.7				
	Total CNS disorders*	7.8	-3.9	42.0	17.6	+5.5	-6.1				

Plan -- FYE March 2018						
H1 (Q1-Q2) Initial Plan	H1 (Q1-Q2) Results	YoY Change	H2 (Q3-Q4) Revised Plan	YoY Change	Full-year Revised Plan	YoY Change
		%		%		%
28.7	25.8	+4.7	33.4	+16.0	59.3	+10.8
3.8	3.4	-20.9	4.1	-25.0	7.5	-23.2
10.5	9.7	+1.4	10.7	+9.3	20.5	+5.4
1.5	1.3	+140.2	2.4	+216.9	3.7	+184.5
1.2	0.4	—	2.9	+274.8	3.4	+332.5
23.4	23.0	+13.2	24.9	+12.5	47.9	+12.9
2.4	2.2	+1.4	2.4	+1.0	4.6	+1.2
1.8	2.1	+153.8	2.4	+76.5	4.6	+106.3
18.0	17.6	+3.3	19.9	+0.3	37.5	+1.7
18.7	17.6	+5.5	20.3	+19.6	37.3	+10.8

FYE March 2017		Q1		Q1-Q2			Q1-Q3		Full-year				
		YoY Change	H1 Plan	YoY Change	vs. H1 Plan	YoY Change	Full-year Plan	YoY Change	vs. Full-year Plan				
			Achievement Rate							Achievement Rate			
		%	%	%	%	%	%	%	%				
Ethical pharma ceuticals	Total brand name drugs	11.3	-11.3	43.9	24.6	-3.5	-4.6	40.7	-0.1	73.8	53.5	+0.5	-3.0
	MEIACT	1.9	-36.6	41.8	4.3	-30.0	-10.0	7.4	-28.0	74.1	9.7	-27.0	-3.2
	ORAPENEM	0.4	-12.3	48.3	0.8	-7.1	-7.4	1.6	-7.3	77.8	2.0	-10.3	+0.4
	REFLEX	4.6	+4.1	49.1	9.6	+4.6	+2.8	14.8	+3.3	73.8	19.4	+2.4	-3.0
	Total generic drugs	9.7	-4.4	45.3	20.3	-1.8	-5.0	31.9	-2.7	75.5	42.5	-1.3	+0.4
	AMLODIPINE	1.0	-20.4	40.6	2.2	-17.8	-14.9	3.4	-19.0	76.5	4.6	-16.4	+1.8
	DONEPEZIL	0.6	-20.8	38.3	1.4	-20.2	-20.6	2.1	-21.5	80.5	2.8	-19.2	+5.0
(By field)	Total infectious diseases*	8.0	-16.7	47.6	17.1	-11.3	+1.0	28.1	-10.3	77.2	36.6	-10.1	+0.4
	Total CNS disorders*	8.1	+4.5	51.3	16.7	+3.9	+4.5	25.6	+2.3	74.8	33.7	+2.9	-1.6
Export	MEIACT	0.6	-28.9	60.5	0.9	-40.3	-6.6	1.5	-29.8	72.6	2.2	-8.2	+3.2
Agric.	ORYZEMATE	0.3	-2.6	79.2	0.4	+2.8	+2.4	1.0	-15.2	16.3	6.6	+0.0	-0.3

Results -- FYE March 2017						
	H1 (Q1-Q2)	YoY Change	H2 (Q3-Q4)	YoY Change	Full-year	YoY Change
		%		%		%
	24.6	-3.5	28.8	+4.3	53.5	+0.5
	4.3	-30.0	5.4	-24.6	9.7	-27.0
	0.8	-7.1	1.2	-12.5	2.0	-10.3
	9.6	+4.6	9.8	+0.4	19.4	+2.4
	20.3	-1.8	22.1	-0.8	42.5	-1.3
	2.2	-17.8	2.3	-15.0	4.6	-16.4
	1.4	-20.2	1.4	-18.0	2.8	-19.2
	17.1	-11.3	19.5	-9.1	36.6	-10.1
	16.7	+3.9	17.0	+2.0	33.7	+2.9
	0.9	-40.3	1.2	+51.8	2.2	-8.2
	0.4	+2.8	6.1	-0.2	6.6	+0.0

Note: Total for brand name and generic drugs in the infectious diseases and the CNS disorders fields

Note: Figures of total infectious diseases for the first quarter are revised on November 8, 2017.

8. Other

1. (Ref.) Net Sales of Exports and Foreign Consolidated Group Companies

(Billions of yen)

FYE March 2018	Q1		Q1-Q2		Q1-Q3		Full-year		Plan -- FYE March 2018							
	YoY Change	H1 Plan Achievement Rate	YoY Change	vs. H1 Plan	YoY Change	Full-year Plan Achievement Rate	YoY Change	vs. Full-year Plan	H1 (Q1-Q2) Initial Plan	H1 (Q1-Q2) Results	YoY Change	H2 (Q3-Q4) Initial Plan	YoY Change	Full-year Revised Plan	YoY Change	
Food segment	9.2	% +4.7	% 49.8	20.9	% +15.5	% +12.9										
Pharmaceuticals segment	8.9	-1.8	48.5	18.8	-0.8	+2.6										

FYE March 2017	Q1		Q1-Q2		Q1-Q3		Full-year		Results -- FYE March 2017							
	YoY Change	H1 Plan Achievement Rate	YoY Change	vs. H1 Plan	YoY Change	Full-year Plan Achievement Rate	YoY Change	vs. Full-year Plan	H1 (Q1-Q2)	YoY Change	H2 (Q3-Q4)	YoY Change	Full-year	YoY Change		
Food segment	8.8	% +12.0	% 43.0	18.1	% +2.6	% -11.6	28.0	% -1.1	% 73.5	38.1	% -0.4	% +0.0				
Pharmaceuticals segment	9.0	-15.8	41.4	19.0	-8.8	-13.3	28.0	-7.6	74.1	38.7	-7.7	+2.5				

Note : Net sales for the parent company export business and net sales (after elimination) from international subsidiaries subject to the scope of consolidation are indicated as above reference information.

2. List of New Products Under Development

Stage	Name	Type	Efficacy Classification	Notes
Approved	Depromel SME3110 (Fluvoxamine)	Oral	Selective serotonin reuptake inhibitor (SSRI) (Pediatric OCD) (Additional indications)	Co-development: AbbVie G.K.
Phase III	ME2112 (Ziprasidone)	Oral	Antipsychotic	In-license: RaQualia Pharma Inc.
Phase II/III	ME2125 (Safinamide)	Oral	Anti-Parkinson's Disease	In-license: Newron Pharmaceutical S.p.A. (Italy) Licensed out to Eisai Co., Ltd. (Japan)
Phase II (International collaborative clinical trial)	SP-02L (darinaparsin)	Injection	Relapsed or refractory peripheral T-cell lymphoma (PTCL)	In-license: Solasia Pharma K.K.
Phase II	REFLEX Org3770 (Mirtazapine)	Oral	Fibromyalgia treatment (Additional indications)	In-license: MSD K.K.
Phase II (Overseas)	ME1111	Topical	Antionychomycosis	Meiji Seika Pharma Co., Ltd.
Phase I	DMB-3111	Injection	Breast cancer/Gastric cancer (Biosimilar)	Co-development: Dong-A Socio Holdings Co., Ltd. (South Korea) Licensed out to Gedeon Richter Plc. (Hungary)
	DMB-3113	Injection	Rheumatoid Arthritis/TNF α inhibitor (Biosimilar)	Co-development: Dong-A ST (South Korea)
	OP0595	Injection	β -lactamase inhibitor	Licensed out to F. Hoffman-La Roche (Switzerland)
Phase I (Overseas)	ME1100 (Arbekacin)	Inhalation	Hospital Acquired Bacterial Pneumonia/ Ventilator Associated Bacterial Pneumonia treatment (HABP/VABP)	Meiji Seika Pharma Co., Ltd.